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Jeffrey S. Miller,1 Edus H. Warren,2 Marcel R. M. van den Brink,3 Jerome Ritz,4
Warren D. Shlomchik,5 William J. Murphy,6 A. John Barrett,7 Hans Jochem Kolb,8
Sergio Giralt,9 Michael R. Bishop,10 Bruce R. Blazar,1 J. H. Frederik Falkenburg11The success of allogeneic hematopoietic stem cell transplantation (HSCT) depends on the infusion of benign
stem cells as well as lymphocytes capable of participating in a graft-versus-tumor/leukemia (GVL) reaction.
Clinical proof of concept is derived from studies showing increased relapse after the infusion of lymphocyte
depleted hematopoietic grafts as well as the therapeutic efficacy of donor lymphocyte infusions without
chemotherapy to treat relapse in some diseases. Despite this knowledge, relapse after allogeneic HSCT is
common with rates approaching 40% in those with high-risk disease. In this review, we cover the basic
biology and potential application to exploit adaptive T cell responses, minor histocompatibility antigens, con-
traction and suppression mechanisms that hinder immune responses, adaptive B cell responses and innate
NK cell responses, all orchestrated in a GVL reaction. Optimal strategies to precisely balance immune
responses to favor GVL without harmful graft-versus-host disease (GVHD) are needed to protect against
relapse, treat persistent disease and improve disease-free survival after HSCT.
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(HSCT) has been successfully used in patients receiving
myeloablative (MA) chemotherapy and irradiation for
the treatment of a variety of hematologic malignancies.
Initially, dose intensification to induce a maximal
antitumor effect was considered essential. Because
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immune effector cells, primarily T cells, were not only
responsible for the development of GVHD, but also
for the reduced risk of relapse. As such, depletion of T
cells from the graft to prevent GVHD resulted in an
increased incidence of relapse after transplantation indi-
cating that donor T cells were capable of mediating
a graft-versus-leukemia/lymphoma (GVL) effect. Be-
cause transplantation with a T cell-replete graft from
a homozygous twin did not result in GVL reactivity, it
was concluded that the mere presence of T cells in the
graft expressing a broad repertoire of specificities was
not sufficient to mediate GVL reactivity, but that allor-
eactive T cells per se were responsible for the antitumor
effect. Further proof of the capacity of donor-derived
T cells to mediate a curative GVL effect came from
the administration of donor lymphocytes to patients
with recurrence of their malignancy after allogeneic
HSCT. Donor lymphocyte infusion (DLI) as a treat-
ment for recurrence of the malignant disease has
resulted in 20% to 90%complete remissions depending
on the malignancy. Chronic myelogenous leukemia
(CML) in chronic phase (CP) was found to bemost sus-
ceptible to DLI, but also patients treated for relapsed
acutemyelogenous leukemia (AML),multiplemyeloma
(MM), chronic lymphocytic leukemia (CLL), or non-
Hodgkin lymphoma (NHL), and a few patients with
acute lymphoblastic leukemia (ALL), showed clinically
evident responses.
Although T cells mediate an antitumor effect
following allogeneic HSCT, in HLA mismatched
transplantations, complete removal of T cells of donor
origin did not result in full abrogation of the GVL
effect. Alloreactive natural killer (NK) cells of donor
origin present in the graft or developing from donor
stem cells following transplantation were also found
to be capable of mediating an antitumor effect. Thus,
T cells and NK cells make use of the genetic disparity
between donor and recipient, resulting in better DFS
in patients with high-risk hematologic malignancies.
In addition, the role of donor antihost antibodies
developing after allogeneic HSCT may also play
a role in antitumor effects and GVHD.
From these observations, it can be concluded that
the main advantage of allogeneic HSCT over autolo-
gousHSCT is the exploitation of the immune response
to further eradicate the malignancy. This insight into
the immunobiology of allogeneic HSCT has led to
the development of strategies to reduce the intensity
of the conditioning regimens to limit the toxicity of
the transplant procedure. Reduced-intensity condi-
tioning (RIC) using profound immunodepletion of
the recipient instead of full myeloablation has greatly
increased the applicability of allogeneic HSCT, allow-
ing treatment of elderly patients with limited
transplant-related morbidity and mortality. RIC has
also changed the balance between donor and recipientcells following transplantation. This may change the
balance between GVHD and GVL in favor of the anti-
tumor response, which can improve the outcome of
allogeneic HSCT with a better quality of life.
To allow appropriate execution of the immune-
mediated antitumor effects, several immunologic
phenomena have to take place. First, immune cells
have to be activated in vivo or in vitro leading to the
appropriate production and expansion of T cells, NK
cells, or antibody-producing cells. Cells and allo-
antibodies have to localize to the tumor sites and medi-
ate effectormechanisms, resulting in tumor destruction.
Preferentially, following a contraction phase of the im-
mune response, a memory response should develop
capable of sustained antitumor control. In this report,
we will discuss several aspects known to play a role in
the development and execution of the immune
response, and also try to identify missing links in under-
standing the biology of the immune reaction. Insight in
these reactivities will lead to more specifically directed
immune responses following transplantation, leading
to increased antitumor reactivity with decreased immu-
nologic complications following allogeneic HSCT.ADAPTIVE T CELL-IMMUNE RESPONSES
T Cell Phenotype: Naı¨ve/Effector/Memory
Naı¨veTcells develop in vivo following aneducation
and selection process in the thymus, and circulate and
migrate to lymphatic tissues to be activated upon en-
countering their specific target antigen. Following acti-
vation, they expand and execute their function, and
following a contraction phase, a subset of T cells be-
comes memory cells, ready to be activated upon
renewed antigen exposure. During life, an expanding
repertoire of antigen-experienced T cells develops, de-
pending on the exposure to foreign antigens. Thus, the
donor T cell repertoire infused into the patient will be
heterogeneous and will depend on the immunologic
history of the donor. The donor T cells can be divided
into naı¨ve (TN; never antigen-activated), effector (TE;
recently activated), and memory T cells (TM), which
can be classified further into effector memory (TEM)
and central memory cells (TCM) [1,2]. Because of the
fact that the TM subset only contains T cells that have
been activated in the past, the T cell receptor (TCR)
repertoire of TM is more narrow than TN. However,
because TM have a lower threshold for activation than
TN , if the donor T cell repertoire contains TM that
can recognize recipient tissues, these cells may be
readily activated after infusion, leading to an in vivo
immune response. Donor T cells have diverse
activation histories, which can impact their ability to
mediate GVL and GVHD. The T cell subsets differ
in various ways, including how they traffic, become
activated, expand, and function after infusion. These
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cell subsets have an impact on GVL mediated by poly-
clonal unmanipulated donorT cell infusions.TN,TEM,
and TCM cells can all potentially mediate GVL [3-5],
although it is likely that TEM are the least potent in
curing tumors because of their reduced ability to
expand after transfer [4]. It is not likely that simple sep-
aration of the T cell subsets before infusion will lead to
induction of GVL without GVHD.
Separation of GVHD from GVL and improve-
ment of effectiveness and specificity of GVL may be
obtained by in vitro selection or expansion of antigen
specific T cells, or with genetically modified T cells
with redirected specificities. For adoptive transfer of
in vitro selected and expanded T cells with defined
specificities, TCM cells may be ideal [6,7]. Yet, some
studies indicate that TN rather than TCM cells are
superior after gene modification and adoptive
transfer [8]. Despite this progress in understanding T
cell biology, the relative contributions of TN or TM
alloreactive T cells to controlling relapse after
transplantation is unknown, and may depend on the
repertoire of the donor, and the genetic disparity
between donor and recipient.Antigen Presentation and Antigen-Presenting
Cells
In allogeneicHSCT, CD41 andCD81T cells that
mediate GVL must interact with major histocompati-
bility complex (MHC)/peptide complexes present on
leukemia target cells [9-11]. In the context of HLA
matched transplantation most leukemia-reactive, mi-
nor histocompatibility antigen (mHA) specific T cells
are TN. These T cells must likely be primed by profes-
sional antigen presenting cells (APCs) to be appropri-
ately activated in vivo, although the precise roles of
APC subsets (dendritic cells [DC], macrophages, B
cells) are not well defined. Therefore, an effective
GVL responsemay require that professional APCs pre-
senting the antigens expressed by leukemia cells or that
the leukemic cells themselves acting as professional
APCs, as may be the case in CML, are present to pro-
voke a T cell response of a sufficient magnitude. Early
after transplant, when there are residual conditioning
regimen-resistant host APCs, direct presentation of an-
tigens derived fromgenes endogenously coexpressed by
APCs and themalignant cells likely provides a sufficient
source of antigen to drive effective GVL; and data in
mouse models support this hypothesis [9,12]. The
kinetics of an appropriate mHA-reactive T cell
response show early activation, expansion, and then
a decline, typically mimicking T cell responses in path-
ogen systems [13,14]. Because a maximal GVL effect
may require a sustained response, this may be
achieved by repeated stimulation of initially activated
cells, new recruitment of T cells directed against thesespecificities, or subsequent activation of T cells
directed against other antigens.
If host hematopoiesis after transplantation is
completely replaced by cells of donor origin, including
donor-derived APCs, and the immune response cannot
be directly triggered by leukemic APCs, the recipient
(malignancy) associated antigens cannot be endoge-
nously presented by professionalAPC.Under those cir-
cumstances, donor T cell activation has to be triggered
by host antigens that are crosspresented by donor APCs
[15]. Mouse models have demonstrated that indirect
presentation occurs, althoughhoweffective this process
is after transplant is less well studied [10,15-17]. Late-
onset GVHD in clinical allogeneic HSCT, when full
donor chimerism has developed, may indicate that
this also occurs in humans. If at this time indirectly pre-
sented host antigens are derived from nonhemato-
poietic cells, it is possible that the host mHAs targeted
may not be expressed on leukemia cells, leading to
GVHD, but not GVL. If allo-immunity is directed
against ubiquitously expressed host antigens, both
GVHD and GVL can be expected. This type of im-
mune response may be sustained because of continuous
antigen access for donor-derived APCs; although the
continuous host antigen/peptide exposure to donor T
cells can also lead to trapping or consumption of allor-
eactive and potentially GVL-inducing T cells in tissues
[18] and T cell exhaustion [19,20]. To induce
crosspresentation, activation signals are likely
necessary. In mouse models, CD4 ‘‘help’’ by CD40L-
expressing T cells, type I interferons (IFN), and
Toll-like receptor (TLR) ligation all promote crosspre-
sentation [21-26]. How to exploit these mechanisms in
patientswho relapse after transplantation is less clear. In
a patient who has relapsed, the standard approach is to
first withdraw immunosuppressive drugs, and, if this is
ineffective, to administer DLI. These are both T cell-
directed interventions, and little attention is paid to
theAPCcomponent of the response. Possible strategies
that would target the APC component could include
adding vaccination against hematopoietically expressed
host mHAs or stimuli that promote crosspresentation
of host antigens by donor APCs.T Cell Allo-Activation (Signal 1)
If allogeneic HSCT is performed over HLA
barriers, a profound immune response is likely to occur.
Allogeneic T cell responses against HLA antigens are
comprised of multiple responses directed against a vari-
ety of peptides presented in the context of nonself HLA
molecules. These T cell responses are caused by normal
T cells educated to recognize foreign peptides in the
context of self MHC, but are crossreactive with unre-
lated antigens when presented in the context of nonself
MHC molecules. As a consequence, these T cell re-
sponses are present in both the TN and the TM
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HLA-mismatched HSCT, TM cells, capable of recog-
nizing a variety of antigens presented in various tissues
of the recipient, will be infused. Because TM cells can
be activated in the absence of professional APCs,
severe GVHD is more likely to occur if patients are
transplanted with HLA-mismatched donor grafts. On
the other hand, if patients are transplanted with a donor
graft from a very young individual or umbilical cord
blood, the likelihoodof largenumbers of donorTMcells
capable of recognizing allo-HLA antigens is more lim-
ited, and therefore, grafts from umbilical cord blood
or very young donors are less likely to cause this severe
type ofGVHDbecause the allo-HLA-directedTN cells
must be activated by professional APCs. If allo-HLA re-
sponses develop, they will be directed against both nor-
mal andmalignant target cells, leading tobothGVLand
GVHD.AfterHLA-matched transplantation, themHA
presentedand recognized in the context of selfMHCare
less likely tobepreviously encounteredbydonorTcells,
and therefore, professional APCs with additional costi-
mulatorymolecules play a more crucial role in the initi-
ation of the allo-immune response. If primary immune
responses against hematopoiesis-associated host mHA
(discussed in detail below) expressed by the APCs
develop, these T cell responses may lead to separation
of GVL and GVHD, whereas transplantation over
HLAbarriers are likely to cause immune responses lead-
ing to both GVHD and GVL reactivity.T Cell Allo-Activation (Signals 2 and 3)
Costimulatory molecules that deliver a second sig-
nal to donor T cells can play pivotal roles in the donor
TN cell activation required for GVHD induction. The
most well-studied pathway, CD28/CTLA-4:B7,
involves homologs that can deliver positive (CD28/
B7) or negative (CTLA-4/B7) interactions. Specific
blockade of the positive pathway reduces GVHD,
whereas blockade of the inhibitory pathway increases
GVHD lethality [27].OtherCD28 familymembers in-
clude inducible costimulator (ICOS) and the pro-
grammed death-1 (PD-1) pathways. ICOS is present
on activated and TM cells, binds ICOS-ligand (a.k.a.
B7h), and promotes TE cell responses [28,29].
Precluding ICOS signals on donor T cells diminishes
donor T cell-mediated alloresponses, especially of the
gastrointestinal tract and liver [30,31], which proved
to be CD41 T cell-dependent disease in some [32],
but not in other studies [33]. Loss of ICOS signaling
worsens CD81 T cell-mediated GVHD, as a conse-
quence of increased expansion of donor CD81 T cells
[33]. PD-1, an inhibitor of activated T cells, also is ex-
pressed in the cytoplasmofCD41CD251Tregulatory
(Treg) cells [32]. Blockade or absence of PD-1 on do-
nor cells accelerates both CD41- and CD81-mediated
GVHD [34].Members of the TNF receptor (TNFR) family
function as costimulatory molecules and modulate
GVHD and GVL. OX40 is present on both activated
CD41 and CD81 T cells as well as on activated
APCs. Despite the presence of the receptor on both
T cell populations, activation of OX40 has been
reported to promote CD41 but not CD81 T cell-
mediated GVHD [35]. CD40 ligand (CD40L) is ex-
pressed on activated CD41T cells, and CD40:CD40L
interaction increases acute GVHD[36] by promoting
CD41 T cell-mediated tissue destruction and CD81
T cell expansion [37]. All 4 of the aforementioned cos-
timulatory pathway members (CD28, ICOS, OX40,
and CD40L) act independently, as inhibition of any
single pathway does not eliminate GVHD, and co-
blockade results in greater protection [38,39]. Two
other TNFR members include 4-1BB and
glucocorticoid-induced tumor necrosis factor receptor
(GITR). 4-1BB is expressed on activated CD41 and
CD81 T cells and on NK cells [40,41]. Inhibition of
4-1BB binding to 4-1BB ligand reduces CD81 T
cell-mediated GVHD lethality and CD41Th1 gener-
ation in GVHD [42,43]. GITR is expressed
constitutively on CD41CD251 Treg cells and
activated CD41CD252 and CD81CD252 T cells
[44]. Stimulating GITR on Treg cells or removal of
GITR1 cells reverses suppression, leading to the de-
velopment of autoimmune disease [44]. GITR stimu-
lation on CD41CD252 T cells reduced GVHD in
MHC II-disparate recipients, whereas stimulation of
GITR of CD81CD252T cells increased proliferation
and GVHD in a MHC I-disparate murine model [45].
In addition to signals 1 and 2, activation of naı¨ve
CD81 T cells to undergo clonal expansion and de-
velop effector function requires a third signal that
can be delivered by IL-12, type I interferon (IFN), or
adjuvant. The third signal, most important when anti-
gen levels are low [46], results in the upregulation of
bcl3 [47] and granzyme B expression [48]. Even at
high antigen levels, the third signal, although not
needed for proliferation, is necessary for the full devel-
opment of cytolytic effector function [46]. The third
signal is critical in determining whether stimulation
by antigen results in tolerance versus development of
effector function and establishment of a responsive
memory population. Prolonged exposure to antigen
and costimulation, along with a third signal are
required for CD81 T cell clonal expansion. Impor-
tantly, signal 3 availability at the tumor site can
influence CD81T cell responses to a solid tumor [49].T Cell Trafficking
Manipulation of T cell trafficking may be an
attractive strategy to separate GVL and GVHD.
Trafficking and migration involve a complex series of
events mediated by integrins, chemokine receptors,
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interaction of these molecules with cognate extracellu-
lar ligands. Selectins (addressins) affecting lymphocyte
migration may also be expressed on endothelial cells of
lymphoid and target tissues [50]. The biologic roles of
homing molecules can be pleiotropic, for example,
contributing to the binding of T cells and APCs at
the immunologic synapse [51].
The CC-chemokine receptor-7 (CCR7) is thought
to play an important role in the entry of naı¨ve lympho-
cytes into secondary lymphoid organs prior to their
activation by APCs, after which it is downregulated as
activated T cells migrate to target tissues to execute
effector functions [52,53]. Individual selectins, integ-
rins, and chemokines/chemokine receptors have all
been implicated in the pathogenesis of GVHD [50].
Chemokine receptorCCR2knockout donorTcells
and b7 integrin knockout donor T cells have both
demonstrated decreased homing to the liver and GI
tract and decreased GVHD, but intact GVL responses
[54-56]. A humanized antibody to the a4 subunit of
certain integrin heterodimers, natalizumab, has been
tested for use in inflammatory bowel disease and
multiple sclerosis [57-61]. Heterodimers with the a4
subunit are important for homing to Peyer’s patches
and gut mucosa, and may thus be useful for blocking
migration of activated T cells to GVHD target sites,
although still permitting activation of GVL effectors
in lymphoid tissue [62]. This hypothesis remains to be
tested, but it is supported by the knowledge that the
a4 subunit forms heterodimers with the b7 subunit
described earlier. Broad questions remain regarding
the function of homingmolecules andT cell trafficking
during GVL, but an assessment of the homing mole-
cules implicated in GVHD presents at least an initial
roadmap [50]. Such studies are necessary to distinguish
molecules critical for GVL from those that may be
blocked to prevent GVHD without impairing GVL.T Cell Cytolysis
Cytotoxic T cell lymphocytes (CTLss) execute
their function via use of the perforin/granzyme system
and death receptor ligands (FasL, tumor necrosis fac-
tor [TNF], TNF-related apoptosis inducing ligand
[TRAIL], tumor necrosis factor-like weak inducer of
apoptosis [TWEAK]), which utilize the target cell’s
own machinery to initiate apoptosis [63]. As with
mechanisms of lymphocyte homing, the role of cyto-
toxicity has been studied in greater detail in GVHD
than in GVL. Most studies have emphasized preserva-
tion of GVL cytotoxicity and suppression of GVHD.
Studies with patient samples have demonstrated vary-
ing levels of leukemic sensitivity to FasL and perforin,
the 2 classic cytotoxic effector molecules [64].
Murine models have suggested the perforin path-
way is important for GVL, whereas FasL appears tohave a greater role in GVHD [63]. However, both
molecules have been implicated in both GVHD and
GVL [63,65,66]. TNF-a, which plays a central role
in GVHD pathogenesis, has also been implicated in
GVL, although it is possible that the GVL effect of
TNF-a may be related to an effect on donor T cells
rather than on host neoplastic cells [10,63,67]. The
role of TWEAK in GVL is unknown, however
TRAIL may have a role limited to GVL without
potential for induction of GVHD63.THE ROLE OF MINOR HISTOCOMPATIBILITY
ANTIGENS IN THE GVL EFFECT
Minor Histocompatibility Antigens
GVHD and GVL activity occur in the majority of
allogeneicHSCT recipients who receive T cell-replete
grafts and/or DLI from genotypically MHC-matched
donors. Thus, GVHD and GVL in this setting are
triggered by donor-recipient genetic disparity at poly-
morphic loci outside the MHC, which are conse-
quently referred to as minor histocompatibility loci.
Studies in both mice and humans have demonstrated
that most minor histocompatibility loci encode short
peptides, termed mHAs, which are encoded by poly-
morphic genes. These are presented on the cell surface
by MHC class I and II molecules, where they can be
recognized by donor CD81 and CD41T cells, respec-
tively. CD81 and CD41 T cell clones specific for re-
cipient mHAs can be isolated from most HSCT
recipients of T-replete grafts or after DLI.
Molecular characterization of mHAs recognized by
T cells after MHC-matched HSCT has demonstrated
that the genetic loci encoding mHAs can be divided
into 2 broad categories based on their chromosomal lo-
cation (Figure 1). The first category comprises a small
class of Y chromosome genes that encode male-
specific mHAs (H-Y antigens), which are targets for fe-
male T cells in sex-mismatched transplants. The genes
encoding all of the known H-Y antigens have X chro-
mosome homologs that encode proteins that are 81%
to 99% identical in sequence with the Y chromosome-
encoded isoforms, and are expressedboth in andoutside
the testis. The extensive sequence disparity between the
Y and X chromosome-encoded isoforms creates a large
number of male-specific peptides that could potentially
serve as targets for female T cells in MHC-matched
transplants. The immunologic significance of H-Y an-
tigens is enhanced by the fact that the Y chromosome
is inherited as a single functional genetic element,
and, therefore, all H-Y antigens are in complete linkage
disequilibrium. At least 12 H-Y antigens encoded by 6
different Y chromosome genes have been identified to
date, and many more remain to be identified.
A heterogeneous group of polymorphic autosomal
loci widely distributed throughout the genome
Figure 1. Chromosomal distribution of the 30 genes known to encode mHAs. The chromosomal locations of the Major Histocompatibility Complex
(MHC), Natural Killer Complex (NKC), and Killer-cell Immunoglobulin-like Receptor (KIR) locus are also indicated.
570 Biol Blood Marrow Transplant 16:565-586, 2010J. S. Miller et al.comprise the second major class of mHA-encoding
genes (Figure 1). Although some of these loci encode
well-characterized proteins with known functions,
there are several whose protein products are as yet com-
pletely uncharacterized. The polymorphism in autoso-
mal minor histocompatibility loci is generated by
variation in human genome sequences, which creates
most of the autosomal mHAs identified to date. Varia-
tion in genome structure, which creates at least 4 known
mHAs, likely creates other mHAs that have yet to be
characterized.Nonsynonymous single nucleotide poly-
morphisms (SNPs) in the coding sequence of normal
self proteins that create amino acid polymorphisms in
the sequence of these proteins createmost of the known
autosomal mHAs. Such polymorphisms can alter how
peptides are generated from self-proteins inside the
proteasome. Peptides are then transported into the en-
doplasmic reticulum by the transporter associated with
antigenprocessing, bind toMHCmolecules, or are rec-
ognized byT cells when presented on the cell surface in
a complex with MHCs. Both mHAs encoded within
normal, as well as alternative open reading frames are
frequently found [68,69]. Alternative mRNA splicing
because of SNPs in the introns of protein-coding genes
[70] and single nucleotide deletions leading to frame-
shift polymorphisms [71] can also createmHAs. Larger
scale variation in the human genome structure creates
mHAs through deletion of entire protein-coding se-
quences. A common deletion polymorphism on chro-
mosome 4q that spans 117 kb and includes the entire
UGT2B17 locus creates at least 3 different mHAs
[72-74].Expression of mHAs in Normal and Malignant
Tissues
Evaluation of the expression of mHAs in normal
and malignant tissues has provided insight into thepotential contributions of mHA-specific T cell
responses to GVL activity. Many mHAs are expressed
inbothhematopoietic andnonhematopoietic cells in vi-
tro, suggesting that T cell responses to these antigens
could contribute to both GVL and GVHD. However,
a significant fraction of mHAs show expression that is
limited to cells of hematopoietic origin, raising the
prospect that T cell responses against these mHAs
might contribute selectively to GVL activity. Because
HLA class II molecules under most conditions are
preferentially expressed on HSCs compared with non-
HSCs HLA-class II restricted mHAs have a higher
likelihood of being selectively expressed by malignant
hematopoietic cells [75-77]. CD41 and CD81 T cell
clones specific for mHAs that are selectively expressed
in HSCs recognize lymphogenous and myelogenous
leukemic cells in vitro and inhibit the growth of
clonogenic leukemic cells in in vitro culture [78,79].
CD81 mHA-specific CTL clones also inhibit the
engraftment of human acute leukemia into nonobese
diabetic/severe combined immunodeficient (NOD/
SCID) mice, demonstrating that leukemic stem cells
[80,81] express mHAs and can be targeted by
mHA-specific CTLs [82,83], which can be active
against established hematopoietic tumors in vivo [84].Contributions of mHA-Specific T Cell
Responses to GVL
Cellular and molecular dissection of immune re-
sponses occurring in recipients after HSCT or DLI
has provided compelling evidence that both autosomal
and H-Y mHAs expressed on recipient tumor cells are
targets of GVL responses in MHC-matched HSCT.
Flow cytometric analysis with mHA peptide/MHC
tetramers has shown that mHA-specific T cells with
in vitro reactivity against recipient leukemic cells in-
crease in frequency in peripheral blood before and
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[68,69,71,85,86]. Analysis of the T cell repertoire in
patients with persistent or recurrent disease who
responded to DLI showed that the T cell response
associated with GVL is polyclonal and likely directed
at a significant number of distinct antigens [87]. Com-
prehensive application of single-cell cloning has
directly confirmed this hypothesis, and demonstrated
that GVL reactions involving T cells with diverse an-
tigen specificity occur in patients with CML [88,89]
and CLL [90].
Retrospective analyses of transplant outcome have
attempted to evaluate the contribution of mHA-
specific T cells to GVL activity by correlating donor-
recipient disparity at specific minor histocompatibility
loci with posttransplant relapse or remission of disease.
Studies that focused on disparity at autosomal mHAs
have had inconsistent results, but the largest of such
studies showed no significant correlation between
donor-recipient disparity at specific loci with tumor
control after HSCT. In contrast, several large retro-
spective analyses have identified a significantly lower
rate of relapse in male recipients of female hematopoi-
etic cell grafts (F/M HSCT) than in any other do-
nor/recipient sex combination, suggesting that T cell
responses to H-Y antigens have a clinically measurable
antileukemic effect [91,92]. Thus, T cell responses
against multiple H-Y antigens are thus likely to be
elicited in any F/MHSCT recipient.
Human Genomic Diversity and the Number of
mHAs
At least 30 different autosomal and Y chromosome
genes have been shown to encode mHAs (Figure 1),
but it is likely that many more mHAs remain to be
identified. The human genome is characterized by an
enormous quantity of sequence and structural varia-
tion. To date, more than 150,000 SNPs that cause
amino acid polymorphisms in the sequence of known
or predicted proteins (www.hapmap.org), and com-
mon deletion polymorphisms that span several dozen
known and predicted genes have been identified.
Thus, there are a very large number of polymorphic
protein and peptide sequences that, in the setting of
MHC-matched allogeneic HSCT, could potentially
encode mHAs. Recognition of the enormous diversity
in the human genome demonstrates that there is abun-
dant polymorphism that could potentially be exploited
to enhance GVL activity after MHC-matched HSCT,
but also suggests that whole-genome approaches to
understanding GVL will likely provide the key to its
successful exploitation.
T Cell Responses to Nonpolymorphic Antigens
In addition to its direct antitumor action, the
mHA-specific T cell response that occurs in recipientsof allogeneic HSCT can enable and recruit antitumor
T cell responses to nonpolymorphic antigens that are
derived from normal self proteins and are over or aber-
rantly expressed in recipient tumor cells. CD81T cells
specific for the HLA-A*0201-restricted PR1 peptide
that is contained within both proteinase-3 and elastase,
the major constituents of the primary azurophil gran-
ules of normal promyelocytes as well as AML and
CML blasts, can be detected in the blood of many
HLA-A*02011 CML patients who achieve remission
after MHC-matched HSCT [93,94]. PR1-specific
CTLs recognize myelogenous leukemia cells in vitro
[95] and inhibit the growth of CML colony-forming
units [96]. The protein product of the WT1 gene is
also a target of spontaneous posttransplant T cell re-
sponses that could contribute to GVL activity against
myelogenous and lymphogenous leukemias. CD81
HLA-A*0201-restricted responses to WT1 have
been observed in HLA-A*02011 ALL patients after
HSCT and their appearance was correlated with clear-
ance of molecular markers of residual disease [97].
Increasing evidence also suggests that donor T cell
responses against recipient tumor-specific antigens
frequently occur in allogeneic HSCT recipients and
could make significant contributions to GVL activity.
Regression of MM in several patients who received
DLI with CD41 cells was associated with the appear-
ance and selective expansion of myeloma-specific
CD81 T cells [98]. Antigens encoded by cancer-
testis (C-T) genes including NY-ESO-1 and the
MAGE and SSX gene families are often expressed in
advanced or poor-prognosis myeloma, and B and T
cell responses to these C-T antigens are preferentially
detected in patients who have undergone allogeneic
HSCT [99]. CML cells express several tumor-
specific antigens that can elicit T cell responses in can-
cer patients, including BCR-ABL junctional peptides,
and BCR-ABL-specific T cells have been detected in
CML patients both before and after HSCT [94]. In re-
cent studies remission of CLL after nonmyeloablative
MHC-matched HSCT was closely associated with
appearance of tumor-specific CD81 T cells [90,100].Role of HLA-DP Mismatch in Unrelated Donor
(URD) Transplantation
Recent genetic and clinical studies suggest that
donor/recipient mismatch at loci within the classical
MHC, most notably at HLA-DP, may play a uniquely
important role in preventing or treating relapse after
transplantation from unrelated donors [101]. High-
density SNP genotyping of 1500 HSCT donor/recip-
ient pairs at the Fred Hutchinson Cancer Research
Center in Seattle has shown that sibling donor/recipi-
ent pairs who are identical at the HLA-A, -B, and -DR
loci are invariably also identical at HLA-C, HLA-DQ,
and HLA-DP, and, in fact, are identical throughout
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This is presumably because of inheritance of the
same 2 copies of chromosome 6 from their parents
(S. Li and E.H. Warren, in preparation). However,
the same is not true for unrelated donor/recipient
pairs, even those who are matched at the DNA se-
quence level at the HLA-A, HLA-B, and HLA-DR
loci. Significant genetic nonidentity within the classi-
cal MHC exists within unrelated donor/recipient pairs
who are otherwise identical at the DNA sequence at
the HLA-A, -B, and -DR, loci, and this nonidentity
is particularly prominent at the HLA-DP locus (S. Li
and E.H. Warren, in preparation). Donor/recipient
mismatch for HLA-DP represents an MHCmismatch
that would be expected to stimulate a polyclonal HLA-
DP-restricted, donor anti-recipient T cell response in
most, if not all, mismatched pairs, and an HLA-DP-
restricted response could potentially have a significant
antitumor effect [101,102]. Two retrospective
analyses, which collectively included more than
10,000 unrelated donor transplants facilitated by the
National Marrow Donor Program and the Japan
Marrow Donor Program, have, in fact, confirmed
that donor/recipient mismatch at HLA-DP is associ-
ated with a statistically significant decrease in the
rate of posttransplant relapse [103,104]. A similar
effect associated with donor/recipient mismatch at
HLA-C was also identified, but the clinical signifi-
cance of HLA-C mismatch is not as great as that asso-
ciated with HLA-DP mismatch because it is observed
in far fewer unrelated donor/recipient pairs (S. Li and
E.H. Warren, in preparation).
In conclusion, genetic disparity between donor and
recipient is the key to the therapeutic efficacy of
HSCT, but is also the root of GVHD, its primary
limitation. Cellular and molecular dissection of GVL
responses have demonstrated that GVL after MHC-
matched HSCT is initiated by donor CD81 and
CD41T cells that recognize recipient mHAs encoded
by polymorphic genes. This alloresponse likely recruits
additional effector cells recognizing tumor-specific or
tumor-associated antigens encoded by nonpolymor-
phic genes that are over or aberrantly expressed in re-
cipient tumor cells. The GVL response in most
HSCT recipients is therefore likely to comprise
a broadly focused immune response directed at a large
number of polymorphic and nonpolymorphic target
antigens. Deeper understanding of the breadth and
the antigenic specificity of theGVLresponsewill be re-
quired to exploit it successfully. Selective expression of
some GVL target antigens in recipient HSCs and
recipient tumor cells, with limited expression in nonhe-
matopoietic tissues, may allow the development of
therapeutic strategies for enhancing GVL activity
without inducing or aggravating GVHD. Character-
ization of the extensive sequence and structural varia-
tion in the human genome suggests that there arelikely to be a large number of polymorphic protein
and peptide sequences at which immunotherapy to
augment GVL could potentially be directed.IMMUNE CONTRACTION AND
SUPPRESSION
Survival of the Organism from a Potentially
Overzealous Immune Response
Analogous to our understanding of tumoriogene-
sis, in which the initial emphasis on oncogenes became
supplantedwith the characterization of tumor suppres-
sors as critical checkpoints that need to be overridden,
there has been an increasing realization that merely
stimulating the immune system in cancer will not be
sufficient. Immune responses to any stimuli eventually
undergo a contraction phase and also induce potent
suppressive pathways, as biologic responses are geared
to end. Immunotherapy in cancer has shown great
promise but has been lacking with sustained responses
and overall survival being affected. In part, this can be
attributed to contraction and suppression pathways in-
herent to the immune response itself and in part be-
cause of manipulation of the suppressive pathways by
the tumor. It has become clear that either augmenting
the immune response in cancer or providing adoptive
immunotherapy will need to overcome these hurdles
to maintain the response. This represents a key path-
way that, despite the successful generation of antitumor
effectors, will limit responses.Naı¨ve T Cell Expansion, Differentiation,
Contraction and Memory T Cell Generation
Whereas cytoreductive antitumor therapies can
reduce disease burden, residual tumor cells must be
eradicated or held in check by the immune system.
The most compelling evidence for a T cell-mediated
immune-mediated antitumor response can be derived
from the adoptive transfer of allogeneic donor lym-
phocytes used to treat leukemia recurrence following
transplantation [105]. Assays for minimal residual dis-
ease in CML have shown a gradual reduction in tumor
burden, often requiring months to years to achieve the
full biologic effect. These data are consistent with
a critical threshold number of antitumor reactive T
cells that is needed to achieve and sustain an antileuke-
mia effect.
Both TN and TM cells can contribute to antitumor
responses.With age and repetitive radiation or chemo-
therapy courses, fewer na¨iveT cells are produced [106].
Under those conditions, TM cells may be the dominant
antitumor reactiveT cell responding population.Naı¨ve
T cells encountering immunogeneic tumor peptides or
antigens can be skewed toward an antileukemia
response, especially during periods of lymphopenia
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kine accumulation (eg, IL-7, IL-15) and substantial T
cell homeostatic expansion and differentiation of naı¨ve
T cells into TE cells that reduce tumor burden [107].
Typically within the first week, a second and profound
contraction phase occurs because of activation-induced
cell death, cytokine consumption, and/or inhibitory
mechanisms (eg, exposure to IFN-gamma or TGF-
b immunosuppressive cytokines, upregulation of
CTLA-4 or PD-1 inhibitory coreceptors or TRAIL
orFaspathwaydeath receptors). Following the contrac-
tion phase, a small subset of antigen-reactive TEM,
TCM, and putative memory stem cells survive, each of
which may retain an antitumor response capacity. In
the presence of CD41 T cell help, posthomeostatic
proliferation-induced memory-like cells are produced,
which can have similar responses to conventional
CD81 TM cells [108]. The precise mechanisms by
which CD41 T cells maintain CD81 T cell memory
are still poorly understood, and this may impact the
efficacy of CD81 T cell transfer.
If tumor antigen levels are sufficient to trigger their
TCR, memory cells may receive survival signals that
promote their persistence and function, thereby per-
mitting further reductions in tumor burden and con-
tinued immune surveillance. If antigen levels are too
high, T cells may become exhausted and are known
to express inhibitory molecules such as PD-1, which
upon engagement by PD-1 ligand (PD-L) render
antigen-reactive T cells hyporesponsive in terms of
proliferation, cytokine production, and killing capacity
[20]. If antigen levels are too low, these memory pop-
ulations would become quiescent until they are reen-
gaged by antigens that trigger their TCR and
sufficient adjuvant signals such as cytokines or costi-
mulatory pathway receptors that can reawaken cells
to proliferate and lyse tumor cells.The Tumor Microenvironment
A key factor that regulates the size and activation
status of thememory cell pool is tissue location. Antitu-
mor reactiveTMcellsmay reside in secondary lymphoid
organs, parenchymal organs, bonemarrow (BM), or the
tumor microenvironment itself. Some but not all of
these environments are conducive to an antitumor re-
sponse by providing positive signals (eg, costimulation,
stimulatory cytokines) and only a limited number of in-
hibitory signals or cell populations that restrain mem-
ory cell activation, expansion, or acquisition of lytic
function. Another key factor in the naı¨ve and memory
T cell response is the capacity of antitumor reactive T
cell tomigrate to the tumor site. Therefore, T cell pop-
ulations not residing at the tumor site, and lacking nec-
essary addressins, selectins, or chemokine receptors for
migration to the tumor site are unlikely to substantively
contribute to the immune response.The immune environment in which TN or TM
cells reside may suppress the antitumor immune re-
sponse by affecting T cell activation, proliferation,
pro- or anti-inflammatory cytokine expression, cyto-
lytic molecule expression, pro- or anti-apoptotic mol-
ecule expression, or the regulation of receptors
involved in migration. The size and activation status
of the TM cell compartment is determined by the bal-
ance between positive and negative signals delivered to
the memory T cell. The positive and negative immune
pathways work in concert, but suppression tends to
trump over stimulation. The lack of the stimulatory
factors may also predispose the immune cells to the
suppressive pathways. These suppressive pathways
may predominate even more in the aged individual,
which may significantly limit immune interventions
in this population. Typically, the tumor highjacks its
microenvironment to foster tumor growth and dis-
courage a productive immune response. Tumor cells
such as those seen in Hodgkin lymphoma cells can
produce immunosuppressive cytokines, such as IL-10
or TGF, which suppress T cell proliferation or induce
Tregs that constrain TE-cell responses in the tumor
microenvironment [109]. Tumor cells can actively at-
tack the attackers by expressing fasL and PD-L [110].
Tumor cells may express high levels of the intracel-
lular tryptophan catabolic pathway, indoleamine 2,3
dioxygenase (IDO), as has been demonstrated for
AML cells [111]. In addition, CD11c1CD191 plasma-
cytoid dendritic cells (pDC) present in draining lymph
nodes or the tumor microenvironment of rodents and
humans can express high levels of IDO, which may be
upregulated by tumor cells (eg, melanoma, breast can-
cer), Toll-like receptor-9 (TLR-9) ligation from expo-
sure to bacteria products, or the T cell response itself
via the elaboration of IFN-g or surface expression of
CTLA-4 [112]. High IDO levels act in the local micro-
environment to stimulate integrated stress response
pathways in T cells activated by amino acid starvation
resulting in cell cycle arrest or apoptosis. In rodents,
IDO expression in pDC has been shown to augment
mature Tregs, and, upon TLR-9 ligation, blocks the
conversion of Tregs into Th17-like cells [113], while
in humans, TLR-9-activated pDC can convert naı¨ve
T cells into Tregs [114].
Tumors can cause T cell dysfunction by altering
TCR signaling mechanisms [115]. Depletion of the
amino acid L-arginine by cytoplasmic arginase I pro-
foundly inhibits CD41 and CD81 T cell functions
[116]. L-arginine depletion is associated with the
downregulation of the TCR zeta chain in T cells that
infiltrate in the tumor microenvironment. Arginase I
is expressed at high levels in myeloid-derived suppres-
sor cells (MDSCs) that infiltrate the tumor microenvi-
ronment [116]. Murine MDSCs have been shown to
have an increased uptake of L-arginine because of
high levels of a cationic amino acid transporter, 2B
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MDSCs,whichmost likely contributes to immune sup-
pression in the tumor microenvironment [118]. In hu-
mans, MDSCs are CD341CD331CD131, indicative
of a myeloid lineage [119]. In mice, Gr-1low-
CD11bhighLy-6ChighSSClow and Gr-1highCD11blow
cell fractions possessed suppressive potential [119].
The latter cells coexpressed F4/80, high levels of
Ly6C, and low levels ofCSF-1 receptor (CD115). Sup-
pression was observed, albeit at as lesser potency on
a cell-by-cell basis for Gr-1hiCD11bhi cells. IFN-g or
lipopolysaccharide not only activatesMDSCs, but sup-
presses the differentiation of DCs from BM myeloid
progenitors. Therefore, an inflammatory response to
tumor cells can result in the generation of MDSCs in
the tumor microenvironment, offsetting the host anti-
tumor immune response. Intriguingly, in patients with
renal cell carcinoma, IL-2 therapy markedly increased
MDSC percentages and arginase I levels [120]. Thus,
IL-2 has a dual effect on the immune response by in-
creasing TE cells and NK cells as well as Tregs and
MDSCs. MDSCs also can suppress T cell function
via other mechanisms such as the elaboration of nitric
oxide or regulation of CD80 and PD-L expression.
Vascular endothelial cell growth factor (VEGF),
known to be produced by almost all tumor cells, has
been shown to inhibit the development of DC from
the BMwhichwas associatedwith an increase in imma-
ture, immune suppressive Gr11myeloid cells [121]. In
some types of cancer patients, immature DCs, in fact,
are increased in the peripheral blood of patients.
A functional state of tumor-mediated suppression
may occur as a result of deviation of the immune re-
sponse toward a nonfavorable TE cell phenotype (eg,
Tregs type I; anti-inflammatory cytokine producing
Th2 cells; TGF-b-secreting Th3 cells). Alternatively,
tumor cellsmay inhibit antigen recognition by a variety
of mechanisms. For example, some tumors downregu-
late major histocompatibility complex antigens (eg,
MHC class I in neuroblastoma cells) or potentially im-
munodominant antigens (eg, EBV nuclear antigens,
3A, B, C in Hodgkin disease). Tumor cells can also se-
crete ‘‘decoy’’ molecules such as soluble MICA, which
can inhibit NKG2D-mediated killing by NK cells.
Defective APC function has been reported in cancer
patients as a consequence of low expression of costi-
mulatory molecules (eg, B7 ligands), exposure to
high levels of IL-10 that result in tolerogenic DC, or
high expression of inhibitory coreceptors (eg, PD-L).Therapeutic Strategies to Overcome Immune
Contraction and Suppression
Bypassing activation-induced cell death (AICD) is
critical for sustaining activated immune cell engraft-
ment and function. However, many cytokines and
pathways can exert opposing effects. IFN-g is a majormediator that is critical for many antitumor effector
functions as well as a major mediator limiting T
cell responses, particularly CD41 T cells via AICD
[122]. During T cell activation, CD25 (IL-2Ra chain)
is upregulated, followed by the downregulation of
CD127 (IL-7Ra chain) at the time of TE cell to effec-
tor/memory transition. As such, it is reasonable to
consider the use of IL-2 or IL-7 to expand TE cells.
However, the biology of IL-7 and other cytokines
such as IL-15 is complicated because of the effects
of presentation of the cytokine by DC’s potentially
yielding opposing effects on the T cell [123]. More-
over, the consumption of cytokines that can occur
during the expansion phase, particularly following
lymphopenia and homeostatic expansion, may result
in a relative deficiency of cytokines to support acti-
vated TE cells. Exogenous IL-2 administration has
been shown to increase TE cells as well as NK cells
and Tregs. Of note, high doses of IL-2 can cause
AICD of activated T cells, and IL-2 withdrawal can
cause cytokine-deprivation induced apoptosis. There-
fore, the available levels of IL-2 for IL-2R engage-
ment are critical in determining the ultimate T cell
fate. Recent data suggest that the binding of IL-2
with an antibody can result in supraphysiologic
effects in vivo and even bypass the need of NK cells
for IL-15 [124,125]. In rodents, IL-7, the second
member of the IL-2R common gamma chain family
of cytokines, has been shown to be a critical growth
factor for CD81 TE and TM cell survival. In humans,
exogenous IL-7 supported a sustained increase in pe-
ripheral blood CD41 and CD81 T cells with broad-
ening of the TCR repertoire diversity, induced T cell
cycling and antiapoptotic protein (bcl2) upregulation,
and expanded TN cells, with a proportional diminu-
tion in Treg frequency [126]. Because IL-7 was well
tolerated in this first in-human study, IL-7 adminis-
tration may prove especially useful in situations in
which IL-7 levels are limiting such as following
homeostatic expansion during the resolving lympho-
penia phase.
IL-15, the third member of the IL-2R common
gamma chain family of cytokines, has been shown to
be essential for memory cell survival. In vivo studies
in rodent and nonhuman primates have demonstrated
the capacity of IL-15 administration to facilitate T cell
survival, especially antigen-specific central memory T
cells. Studies of human T cells indicate that IL-15
favors the in vitro generation of TCM versus TE cells
and also appears to be critical for NK cell survival.
IL-15 is being readied for first-in-human testing in
the near future. However, the ‘‘trans’’ presentation
that IL-15 appears to require for optimal effects sug-
gests that simple administration of the cytokine may
not be sufficient [127]. IL-21, the fourth member of
this family that is closely related to IL-2, also promotes
the function of CD81 TE cells [128]. In contrast to
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into granzyme B- and CD44-expressing effector
CD81 CTL [129]. At the same time, IL-21 increased
the antitumor regressive capacity of adoptively trans-
ferred CTL. These data are consistent with the para-
digm that cytokines, such as IL-21, limit both the
stage of TE cell differentiation and preserve the
expression of key cell surface homing receptors such
as L-selectin. Thus, IL-7, IL-15, and IL-21 are new
candidate cytokines that may favor the persistence of
TM cells with improved antitumor properties, com-
pared to IL-2. New approaches for cytokine delivery,
such as cytokine-anticytokine antibody complexes
may provide a superior methodology to achieve more
pronounced in vivo biologic effects by increasing their
otherwise short serum half-life.
Thus far, the success of bypassing negative regula-
tors (eg, CTLA-4 or PD-1 pathway blockade for T
cells, killer inhibitory receptor blockade for NK cells)
may result in augmented antitumor effects but may
also result in possible autoreactive toxicities. For
example, antibodies directed against CTLA-4 have
shown promising results in clinical trials in augment-
ing endogenous antitumor reactive T cells, while at
the same time inducing autoimmune-mediated
destruction of nontumor cells in some patients [130].
Anti-PD-1 and anti-PD-L1 antibodies are in clinical
trials in cancer patients; anti-PD-L1 antibody may be
particularly useful in preventing the T cell exhaustion
state that chronic antigen activation may cause [20].
However, in vivo studies have suggested that targeting
multiple members of the PD1/PD-L family may be
needed for optimal effects. Agonistic antibodies
against costimulatory pathway members (eg, CD40/
CD40L, OX40/OX40L, 4-1BB/4-1BBL) alone or
combined with blockade of inhibitory coreceptors
may prove to be particularly efficacious in patients
with both APC and T cell dysfunction.
A chemical inhibitor of the IDO pathway
(1-methyl-tryptophan) is being studied in phase I trials
in cancer patients. COX-2 inhibitors have been used
successfully, especially in patients with solid tumors,
to reverse PGE2-mediated suppression and the
frequency of inducible Tregs that can occur as a result
of the tumor microenvironment [131]. MDSC-
mediated inhibition of antitumor T cell or NK cell im-
mune responses may be overcome by sunitinib malate
[132], a receptor kinase inhibitor, TGF-b neutraliza-
tion [133], modulators of arginine metabolism (see
above) or nitric-oxide synthase inhibitor (eg, N[G]
nitro-L-arginine methyl ester [L-NAME]) [134].
Anti-VEGF antibody in rodent but not human studies
decreases suppressive DC numbers [120,121].
Cellular depletion approaches such as those target-
ing Tregs (eg, IL-2 diphtheria toxin, a.k.a. denileukin
diftitox or Ontak) have been variably efficacious in
augmenting endogenous T cell responses by depletingTregs. The transfer of ex vivo expanded and activated
antitumor reactive T cells, including those that are
forced to express an antitumor reactive TCR by gene
transfer, have been reported to be efficacious in pa-
tients withmelanoma, generally an immune responsive
disease [135]. Rodent studies have indicated that com-
bined in vivo Treg depletion with the adoptive transfer
of syngeneic CTL [136] may be a useful strategy that
circumvents the in vivo dysfunction of antitumor reac-
tive T cells (eg, TCR zeta chain downmodulation) and
inhibits the suppression conferred by Tregs.
The role of CD41 T cells (and the ratio of their
subsets may be critical) in maintaining CD81 T cell
responses (survival and function) also needs to be
explored. More attempts at combination approaches
need to be undertaken. Recent data also suggests that
activated DCs may do more than simply initiate the
adaptive response but may also play a role in maintain-
ing antigen-specific CD81T cell function and survival
[137]. These data indicate that cytoreductive condi-
tioning in HSCTmay do much more than simply pro-
mote T cell expansion via homeostasis, but instead
activates DCs via TLRs. Understanding the mecha-
nisms involved may have a profound impact on the
use of HSCT and adoptive immunotherapy. Finally,
it has been shown in numerous models that peripheral
immune readouts may have no bearing on antitumor
responses. Studies are needed that understand how
normal contraction processes occur within any attempt
to stimulate or provide immune responses. AICD cou-
pled with immune suppression and deprivation of sup-
portive cells and cytokines may prematurely diminish
responses and make the host resistant to further to
attempts at stimulation. Targeting immune responses
to the tumor site and, importantly, assessing immune
effects within the tumor itself, may offer the best indi-
cators of success as well as limit systemic toxicities. Un-
derstanding normal immune contractions/suppression
and how the tumor can further subvert it is critical if the
immune system is to be applied in cancer therapies.ADAPTIVE B CELL-IMMUNE RESPONSES
IN GVL
The Role of B Cells and Antibodies in GVL
Evidence that B cells contribute to tumor immunity
after allogeneic HSCT comes primarily from studies
that have attempted to characterize immunologic events
in patientswith documented effectiveGVL responses in
vivo. For example,Wu et al. [138] studied patients with
relapsedCMLwho responded toDLI. Antibodies reac-
tive with CML cells were identified after DLI response,
and specific protein targets were identified using sero-
logic analysis of recombinant cDNAexpression libraries
(SEREX). Several target proteins were characterized in
greater detail, and it was further shown that the
576 Biol Blood Marrow Transplant 16:565-586, 2010J. S. Miller et al.generation of antibodies specific for these targets coin-
cided with the disappearance of CML cells in vivo. Sim-
ilar antibodieswerenotpresentbefore transplant, before
DLI, or in patients who developed chronic GVHD
(cGVHD) after transplant. Antibodies to these CML-
associated antigens were also not present in healthy do-
nors or in patients who did not respond toDLI. Further
studies demonstrated that several of these target anti-
gens were preferentially expressed in both normal and
CML progenitor cells [139].
Antibody responses to tumor-associated antigens
have also been identified in patients with myeloma
after allogeneic HSCT. Compared with CML, graft-
versus-myeloma (GVM) responses after allogeneic
HSCT occur less frequently and often only result in
partial responses. Patients with myeloma who received
prophylactic DLI early after transplant were found to
have increased numbers of normal polyclonal
CD201 B cells in peripheral blood [140]. Using a sim-
ilar SEREX approach Bellucci et al. [141] identified
a panel of myeloma-associated antigens that were tar-
gets of antibody responses in patients with myeloma
who responded to DLI. Antibody responses were not
detected before DLI or in patients who did not receive
DLI after transplant. These target proteins were
highly expressed in myeloma cells, and antibodies to
some of these antigens were detected in different
DLI responders. Taken together, these studies in
different hematologic malignancies suggest that
polyclonal antibody responses to a variety of tumor-
associated antigens frequently occur in patients with
effective graft-versus-tumor responses in vivo.
Nevertheless, the mechanisms whereby these antibody
responses contribute to elimination of tumor cells in
vivo have not been established.Target Antigens and Potential Mechanisms
of Action of Antibodies
Several studies have reported that posttransplant
patient antibodies can recognize cell membrane pro-
teins expressed on tumor cell targets. This was recently
shown for a polymorphic protein, ILT5, which is ex-
pressed on the cell membrane of normal DC [142].
This antigen is also expressed on myelogenous leuke-
mia cells, and antibodies in patient serum were able to
induce both complement-mediated cytotoxicity of
AML cells as well as antibody-dependent cellular cyto-
toxicity (ADCC). In this instance, immunogenicity was
because of a polymorphism in the ILT5gene.As a result
of this polymorphism, donor B cells were able to recog-
nize a variant of this protein in the transplant recipient
that was not present in theHLA identical transplant do-
nor. Overall, ILT5 reactive antibodies were found in
5.4% of HSCT patients, but not in solid organ
transplant recipients, patients with autoimmune dis-
eases, multiparous women, or healthy individuals.Antibodies to a B cell membrane antigen, BCMA,
have also been found in patients with myeloma [143].
BCMA is a transmembrane receptor of the TNF su-
perfamily that is selectively expressed by mature B
cells. In this setting anti-BCMA antibodies were also
able to induce both complement-mediated cytotoxic-
ity of myeloma cells, as well as ADCC. BCMA
antibodies were only detected in patients with
myeloma who received DLI. However, in this case,
no genetic polymorphism in the BCMA gene was
detected to account for the immunogenicity of this
specific protein. Although few antibodies to cell
membrane proteins have been described, few studies
have specifically attempted to identify these types of
antibodies as current methods that have been used to
determine the specificity of antibodies in patient sera
such as SEREX are not well suited to detect membrane
proteins. It is therefore possible that antibodies to cell
membrane proteins are a more common phenomenon
in patients with GVL.
Most antigens that have been identified as targets of
posttransplant antibodies are intracellular proteins. As
with cell membrane proteins described above, the im-
munogenicity of some of these proteins is because of
genetic polymorphisms that distinguish recipient and
donor. For example, Y chromosome encoded proteins
are immunogenic inmale patientswho receive stemcell
grafts from female donors. Males are tolerant to these
‘‘self’’ antigens, but H-Y proteins are highly
immunogenic in females and elicit bothB andTcell re-
sponses after HSCT. H-Y proteins are widely
expressed in normal tissues as well as tumor cells. B
cell responses to H-Y proteins have been associated
with cGVHD, but patients with antibodies to HY pro-
teins also have a significantly lower risk of relapse after
transplant than patients without H-Y antibodies [144].
In addition to H-Y proteins, a number of other intra-
cellular proteins have been identified as targets of anti-
body responses in patients with GVL [138,141]. In
most of these cases, polymorphisms that distinguish
recipient from donor have not been identified, and
the immunogenicity of these proteins has not been
explained. Nevertheless, the persistence of high titer
IgG antibodies for long periods after transplant
suggests that these proteins are highly immunogenic.
It is also possible that specific T cell responses
directed against peptide epitopes derived from the
same proteins are also present in these patients.
Coordinated B and T cell responses have been
reported for H-Y proteins, and similarly coordinated
responses may also exist for many of these other
proteins [145]. In these cases, the presence of specific
antibodies reactive with soluble proteins or protein
fragments may facilitate antigen presentation and the
development of specific CD41 and CD81 T cell re-
sponses to distinct peptide epitopes contained within
these larger fragments.
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sively, antibodies directed against soluble or secreted
proteins have also been detected after allogeneic
HSCT. Antibodies specific for secreted proteins
may significantly deplete these proteins in vivo, re-
sulting in profound functional effects. For example,
some solid tumor patients who respond to tumor vac-
cines and infusions of anti-CTLA4 antibody have
been found to develop high titer antibodies specific
for soluble MICA [146]. MICA is expressed on tumor
cell membranes in response to DNA damage and is
a known ligand for NKG2D expressed on NK cells
and CD81 TE cells. However, soluble MICA se-
creted by tumor cells results in the downregulation
of NKG2D on NK cells and TE cells with subse-
quent loss of cytolytic function. Antibodies to
MICA induce the clearance of this soluble protein,
resulting in the reexpression of NKG2D and restora-
tion of cytolytic effector cell function. In patients
with AML after allogeneic HSCT, Ho et al. [147] re-
cently reported a decrease in soluble NKG2D ligands
following vaccination with autologous leukemia cells
genetically engineered to secrete granulocyte macro-
phage colony stimulating factor (GM-CSF). Elevated
levels of soluble MICA have also been found after al-
logeneic HSCT [148]. In this study, elevated levels of
anti-MICA were associated with decreased cGVHD
and increased risk of relapse after allogeneic HSCT.
In many patients, the effectiveness of the GVL
response is limited by immune suppressive factors
secreted by the tumor cells themselves. The genera-
tion of specific antibodies directed against immune
suppressive molecules may therefore be an indirect
mechanism whereby donor B cells can promote
GVL responses mediated by other effector cells. Fur-
ther studies are needed to explore this novel mecha-
nism whereby antibodies can potentially contribute
to the GVL response in vivo.
Although the development of B cell responses after
allogeneic HSCT appears to be associated with
effective GVL responses, it has also been noted that
antibodies to tumor cell antigens are frequently found
in patients with solid tumors. In contrast to the post-
transplant setting, the presence of antibodies is not
clearly associated with effective autologous tumor
immunity in patients with solid tumors [149]. A very
large database of antigens identified by SEREX is
now available in the Cancer Immunome Database
(http://ludwig-sun5.unil.ch/CancerImmunomeDB).
In some cases such as NY-ESO-1, T cell responses to
distinct epitopes within these proteins have also been
identified, but the clinical relevance of these endoge-
nous antibody responses has not been established
[150] . In mouse models that have examined the role
of B cells in tumor immunity, it has been found that
the presence of B cells can actually inhibit effective
tumor immunity [151].Methods to Identify Target Antigens
Thus far, most studies that have attempted to de-
fine the specificity of antibodies in the posttransplant
setting have relied on the SEREX approach to identify
and clone specific target proteins. This has been a very
useful tool and has allowed the broad characterization
of antibody specificity. However, the SEREX method
also has limitations, and may not be able to identify all
relevant target antigens. Because target genes are
identified in a cDNA expression library, this method
favors the identification of highly expressed genes
and protein targets represented by low copy number
mRNAs are difficult to detect. This method also
does not favor the identification of cell membrane pro-
teins. Protein microarrays that include very large num-
bers of targets are now available, and these can provide
an alternative approach for identification of antibody
specificity after allogeneicHSCT, especially in the set-
ting of GVL. Protein microarrays have the advantage
of providing an unbiased approach to target identifica-
tion and also greatly simplify and standardize the
procedure for characterizing the specificity of complex
polyclonal antibody responses. Although current
proteinmicroarrays now contain several thousand pro-
teins, this approach also has limitations. Many relevant
proteins may not be included in these arrays, and this
approach is not designed to detect responses specific
for protein polymorphisms. The cost of these arrays
may be prohibitive for large-scale studies, but it is
likely that this will also be a useful approach for
defining antibody specificities in the setting of GVL
responses in vivo.
As methods for high throughput genotyping and
whole genome sequencing continue to evolve rapidly,
it is likely that thesemethods will also facilitate the abil-
ity to identify antibody targets. For example, the identi-
fication of genetic disparities that distinguish recipients
and stem cell transplant donors has already been used to
predict candidate immunogenic targets for GVHD re-
sponses. Using current bioinformatic tools, it is also
possible to identify genetic disparities or mutations
that predict for the creation of immunogenic epitopes.
Once specific epitopes are identified in silico, the immu-
nogenicity of these epitopes can be validated in patients
who have undergone allogeneic HSCT. In the future,
this approach can be used to validate both B and T
cell epitopes and to examinewhether they are associated
with either GVL or GVHD (or both).Mechanisms That Promote Antibody Responses
and Implications for Therapy
The administration of MA or intensely immune
suppressive therapy prior to allogeneic HSCT leads
to profound lymphopenia that often persists for
prolonged periods. The physiologic response to
lymphopenia facilitates the homeostatic proliferation
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these cells to normal levels. In this environment,
recent studies have suggested that B cell recovery
following HSCT is supported, at least in part, by
high levels of B cell activating factor (BAFF)
[152,153]. This homeostatic cytokine promotes B cell
survival and differentiation, and thus supports the
secretion of antibodies generated by donor B cells. As
noted above, these antibodies may contribute to the
GVL response, and the persistence of high levels of
BAFF may therefore be an important mechanism to
support this functional activity. Other cytokines and
microenvironmental factors likely also play important
roles in the reconstitution of B cell numbers and
repertoire following transplant. These factors have
not been well defined in the clinical setting, and
further studies to identify factors that modulate B cell
reconstitution are warranted. As we develop a better
understanding of the role of B cells in the GVL
response in vivo, the characterization of these factors
may provide novel opportunities for modulating B
cell reconstitution to promote GVL after allogeneic
HSCT.
Although B cell responses noted above have been
associated with GVL, it is important to acknowledge
that B cells also likely contribute to the development
of cGVHD after allogeneic HSCT [144,152,154].
This is further supported by the finding that B cell-
directed therapy with anti-CD20 monoclonal
antibody (rituximab) can provide effective therapy for
some patients with steroid-resistant cGVHD
[155-157]. Despite many attempts to distinguish
GVL and GVHD, it is evident that there is
substantial overlap between immune responses
directed against either cancer cells or normal tissues
in the transplant recipient. In this setting, new
approaches to enhance B cell responses to promote
GVL may also have the unwanted toxicity of
increasing cGVHD. Similarly, new and more
effective strategies to treat or prevent cGVHD by
targeting donor B cells may also have the unwanted
effect of reducing GVL and increasing the risk of
relapse after allogeneic HSCT. These issues will
need to be carefully considered in the design and
evaluation of any new clinical strategies to modulate
B cell reconstitution following transplant.INNATE NK CELL IMMUNE RESPONSES
NK Cell Biology
The GVL effect goes beyond adaptive immune
responses, and a role forNK cells has been shown in hu-
mans and the mouse. Yet there are striking species dif-
ferences between themouse and humans that need to be
considered when attempting to translate results. Dom-
inant among these differences is the expression of CD56as a marker on human NK cells and the existence of
CD56bright and CD56dim subsets. CD56bright NK cells
are present in the lymph node and blood in humans,
are highly proliferative, and produce cytokines, but
are weakly lytic, suggesting they exert immunoregula-
tory functions. Mice lack both CD56 as a marker on
their NK cells and have few NK cells in the lymph no-
des. TheMHC binding receptors in the mouse and hu-
mans are also fundamentally different. In humans,
killer-immunoglobulin-like receptors (KIRs) are the
dominant HLA-binding molecules that regulate NK
cell activity, whereas mice express the lectin-binding
Ly49 family. Additionally, mice are housed under spe-
cific pathogen-free (SPF) conditions and their baseline
NK cell killing is relatively poor, which correlates
with very low granzyme/perforin expression unless acti-
vated, whereas human NK cells readily express these
lyticmolecules and exhibit de novo function without ac-
tivation. In addition, human NK cells survive better ex
vivo, whereas murine NK cells inevitably die after 2
weeks in culture. Despite these differences, there are
many similarities in biologic paradigms between human
and mouse NK cells including the expression of regula-
tory molecules (NKG2D, CD94/NKG2A, and others),
lytic pathways, and effects of cytokines (IL-15, IL-2,
Flt3L) critical for their development. Attempts to use
xenograft models to study humanNK cell development
and activity has been inconsistent, but progress has been
made by the discovery that IL-15 trans-presentation by
species specific IL-15Ra is required and warrants fur-
ther study.
Although both human and murine inhibitory
receptors (KIR and Ly49, respectively) recognize
MHC molecules, the natural ligands for many KIRs
are unknown, including all of the activating KIRs,
even though some may bind MHC molecules at low
affinity. In the homologous murine Ly49 system, the
activating receptor Ly49H recognizes the murine
cytomegalovirus (CMV) glycoprotein m157, providing
‘‘proof of principle’’ that activating receptors may rec-
ognize viral proteins. Until recently, it had been pre-
sumed that only cells of the adaptive immune system
have memory. Recently, the Lanier lab has shown that
Ly49H1 (the receptor for muCMV) NK cells dramati-
cally expand and then contract after viral control, yet
amazingly these cells can be found in the recipient 3
months after infection suggesting that ‘‘NK cell mem-
ory’’ exists [158]. A role for human activating receptors
in infection is supported by studies of patients withHIV
showing an association between AIDS progression and
in transplantation by association with humanCMV, but
memory NK cells are not well studied in humans.Development of NK Cell Self-Tolerance
The mechanism by which NK cells acquire self-
tolerance and alloreactivity has been referred to as
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most widely debated topics in NK cell biology over
the past several years. Self-tolerance is the process
by which NK cell function is suppressed after ligation
of ‘‘self’’ through class I recognizing inhibitory recep-
tors. Although alloreactivity is determined by a lack
of inhibition and a positive balance of activating sig-
nals, how an NK cell acquires effector function is
more complicated. Several models have been pro-
posed to explain why inhibitory receptor expression
correlates with the acquisition of effector function.
These concepts differ in their implied mechanisms
and whether the process is one of activation or loss
of function. What is agreed upon between these
and other models is that human NK cells lacking in-
hibitory receptors are hyporesponsive [159-161].
Although the exact mechanism remains unknown,
self-tolerance may be the result of coordinated devel-
opmental pathways whereby mature NK cell function
is synchronized with the acquisition of self-inhibitory
receptors and their subsequent ligation. The com-
plexity of these interactions is highlighted by the ex-
pression of multiple inhibitory receptors capable of
recognizing self-MHC, the net summation of activat-
ing receptor signals and the variable expression of li-
gands resulting in a ‘‘rheostat’’ [162] or a continuum
‘‘tunable rheostat’’ model integrating a cadre of dif-
ferent signals on the NK cell itself and its potential
targets [163]. In humans, the best evidence for NK
cell education is the finding of enhanced function of
self-KIR expressing NK cells (KIRs in an individual
who also expresses its cognate HLA ligand) where
NK cells expressing nonself-KIRs are hyporespon-
sive. Although KIR interactions dominate the clinical
literature, receptors beyond KIR are operant in rheo-
stat models and include class I-recognizing NKG2A
(recognizes HLA-E), LIR-1 (recognizes HLA-A, B,
and G), and class I MHC-independent interactions
including but not limited to: CD16 (FcRIII), natural
cytotoxicity receptors (NKp30, 44, 46), DNAM-1,
LFA-1, NKG2D, and CD244 (2B4).
Above and beyond the control of NK cytotoxicity
by MHC class I expression on tumor cells, we are
beginning to appreciate tissue-specific differences in
the ability of NK cells to kill targets. Most notably,
transplant data suggest that myelogenous malignan-
cies are more susceptible to NK cell control than
lymphogenous malignancies [164,165]. Why
myelogenous cells are more susceptible is not known.
One possibility is that myelogenous leukemias share
with normal myelogenous APCs the activation-
induced C-type lectin (AICL) ligand for NKp80,
another C-type lectin NK cell recetor, which could
license the NK cell for cytotoxicity [166]. AICL is
a myelogenous specific activating receptor that is upre-
gulated by TLR stimulation, suggesting thatinflammationmay primeNK cells to kill targets. Other
differences in receptor-ligand interaction strength
have also been proposed and are presumed to be target
specific. For example, in CML NKG2D interacting
withMICA/B, abundantly expressed on leukemic cells,
appears to be the mechanism of NK cell-target en-
gagement [167]. A critical question in determining
their clinical potential is whether NK cells exhibit cy-
totoxicity against leukemia stem cells. Some data sug-
gest that, at least in CML, NK cells can engage early
leukemic CD341 progenitors, although the cytotoxic-
ity is weak. NK cells exert cytotoxicity via perforin-
granzyme pathways, but recently a role for TRAIL
engagement with TRAIL receptor on the NK cell
has been shown to be important. Strategies to exploit
this mechanism may be of therapeutic importance.
Notably, the proteosomal inhibitor, bortezomib,
upregulates TRAIL and can increase cytotoxicity of
NK cells to renal cell cancer and CML progenitors
[168]. Studies aimed at sensitizing targets to NK cell
killing warrant further study.The Role of NK Cells in the GVL Response
NK cells are attractive to exploit in the setting of
hematopoietic transplantation because they are the
first lymphocytes to reconstitute after transplantation
at a time when the adaptive immune system is
impaired. A number of groups have been interested
in harnessing the activity of NK cells in the setting of
autologous HSCT to prevent relapse, the biggest
cause of treatment failure from this procedure. These
studies employed low-dose IL-2 administration, which
was capable of expanding NK cells in vivo with a mod-
est increase in cytolytic activity. However, even higher
doses of IL-2 and autologous hematopoietic cell infu-
sions were not strong enough to result in significant
clinical benefit when evaluating definitive clinical end-
points such as time to disease progression and relapse.
The biology of NK cells has now explained this result
to be partially a result of (1) a number of class I MHC
‘‘self’’-recognizing inhibitory receptors displayed on
the surface of NK cells, and (2) a consistent finding
that low-dose IL-2 administration may lead to blunt-
ing of the immune response by increasing Tregs.
These 2 issues underpin current strategies to exploit
NK cells in the clinic. The first major advance was
reported by Ruggeri et al. [164], who found a reduced
risk of relapse of leukemia in AML patients who
received transplants from donors who were mis-
matched at HLA-B or HLA-C ligands for KIRs. The
advantages of KIR ligand mismatch appear to be spe-
cific to AML and dependent on potent graft T cell de-
pletion, suggesting that the platform is critically
important to see beneficial effects of early posttrans-
plant therapy. The potential benefits include: (1)
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cells, (2) better antitumor activity via direct cytotoxic-
ity, (3) improved engraftment mediated by NK cell
release of hematopoietic cytokines, and (4) ultimately
better survival. Additional clinical trials have either
supported or failed to find relapse protection and a sur-
vival benefit [169-176], which may be explained by
important differences in transplant platforms
between studies including preparative regimen,
extent of T cell depletion, graft source, donor, stem
cell dose, disease, and disease status. Taken together,
these results suggest that NK cells play a role in
allogeneic HSCT and myeloid leukemia therapy;
however, the complexities of the KIR system and the
presence of other functional receptors on NK cells
may explain some of the confusion in interpreting
published studies.
KIR Genotyping: Implications for Donor
Selection
The role of KIR immunogenetics is complicated
by 16 genes and over 100 allelic polymorphisms,
some of which define distinct functional differences.
Despite these complexities, some simple associations
have been made in determining clinical outcome after
HSCT. Unrelated donors and recipients from 209
HLA-matched and 239 mismatched T-replete URD
transplantations for AML were analyzed by KIR gen-
otyping [177]. Based on gene content, donors were
stratified as having a B/x haplotype if they contained
1 or more B-defining genes (KIR2DS1, 2, 3, 5 and
KIR2DL5), whereas those lacking these genes were
classified as having a KIR A/A haplotype. Three-year
overall survival was significantly higher after trans-
plantation from a KIR B/x donor {31% (95% confi-
dence interval [CI]: 26-36) versus 20% (95% CI: 13-
27); P 5 .007}. Multivariate analysis demonstrated
a 30% improvement in the relative risk of relapse-
free survival with B/x donors. This demonstrates that
unrelated donors with KIR B haplotypes confer signif-
icant survival benefit to patients undergoing T-replete
HSCT for AML. Certain B haplotype KIR groups
have also been found to favorably affect outcome after
T cell-depleted HLA identical sibling transplants
[165]. Thus, it seems likely that the genetic character-
istics of a stem cell donor could affect transplant out-
come; however, data on the relative impact of
specific KIR genes or groups of genes needs further
study to understand why effects are not applicable to
diseases beyond AML.
NK Cell Adoptive Transfer
Much of what is known about lymphocyte adoptive
transfer comes from T cell infusion literature, which
may extrapolate to NK cell therapy. Emerging con-
cepts suggested that in vivo expansion of lymphocyteswere dependent on a potent lymphodepleting regimen
to (1) create space, (2) increase endogenous cytokines,
and (3) to eliminate immune rejection of adoptively
transferred cells. This has been well established in
mouse models and the infusion of carboxyfluorescein
diacetate, succinimidyl ester (CFSE, a fluorescence
dye that gets diluted out in proliferating cells)-
labeled lymphocytes that did not expand in the absence
of a lymphodepleting regimen [178]. This lymphode-
pletion strategy was first translated into humans by
Dudley et al. [179], who demonstrated in vivo expan-
sion of melanoma specific T cells after a preparative
regimen of high-dose cyclophosphamide and fludara-
bine. Because HSCT always uses a lymphodepleting
regimen, whether fully MA or not, the same biologic
concepts for lymphocyte adoptive transfer may be
extrapolated.
In 2005, Miller et al. [180] were the first to show in
vivo expansion of NK cells after adoptive transfer of
haploidentical related donor NK cells. The success of
this regimen was dependent on a lymphodepleting pre-
parative regimen that included cyclophosphamide and
fludarabine. NK cells were infused with IL-2 adminis-
tration for the 2-week interval after adoptive transfer.
Chimerism studies established unequivocal proof of
concept that donor-derived haploidentical NK cells
persisted and expanded in vivo in some patients. How-
ever, this strategy was limited by inadequate efficacy,
which may correlate with failure to expand donor NK
cells in vivo. This could be explained by inadequate po-
tency of the preparative regimen, insufficient cytokines
acting in vivo (endogenous IL-15 induced by lympho-
depletion), or contraction of the immune response by
increasing Treg cells stimulated by IL-2. In an attempt
to overcome some of these barriers several groups have
been exploring increased intensity of a lymphodeplet-
ing regimen with the addition of total body irradiation,
approaching that used in a fully MA preparative
regimen. Although these studies are ongoing, there
are suggestions with both T cell and NK cell adoptive
transfer that a more potent lymphodepleting regimen
may be beneficial. Therefore, to maximize the effects
of adoptive transfer, combination with HSCT may be
warranted to avoid prolonged neutropenia.
One of the challenges in NK cell therapy is how to
maximize the effector to target ratio in vivo, which
likely correlates with efficacy. IL-15 has recently
shown promise in primates [181] and will be made
available through the National Cancer Institute for
clinical testing. Although in vivo expansion of NK cells
is attractive and allows little ex vivo manipulation, an
alternative approach that could also avoid the potential
toxicities of a potent lymphodepleting regimen is to
expand NK cells ex vivo to increase numbers. One
method proposed by Campana et al. [182] uses K562
stimulators transduced with 41BB-ligand and mem-
brane-bound IL-15. Another approach is described
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methods using B cell feeders to promote NK cell ex-
pansion over 500-fold. As one contemplates compara-
tive studies between in vivo and ex vivo expansion
approaches, several questions need to be answered.
Does in vivo expansion lead a more efficient NK cell
education and resultant antitumor function than ex
vivo expansion? How do in vivo and ex vivo expansion
methods affectNK cell activation, receptor expression,
survival, homing, and durability of response? All of
these questions warrant further study.
In conclusion, our understanding of NK cell target
interactions requires more detailed exploration of the
potency of specific NK molecules and their ligands
on specific target cells (including malignant stem
cells), the stages of NK maturation, and the effect of
the recipient milieu on NK cell maturation and NK
clonal selection. Also, relatively little is known about
the homing of NK cells to their targets and whether
NK cells are restricted in the tissues they patrol.
Importantly, we do not yet have a clear idea about
the ultimate potency of NK cells in their most favor-
able context to permanently eliminate malignancy
and to best apply them to the problem of post-
transplant relapse.CONCLUSION
Immune responses following allogeneic HSCT
andDLI have illustrated the robust potential of alloge-
neic T cell, NK cell, and/or antibody responses to treat
patients with hematologic malignancies. Several
issues, however, have limited the successful application
of these immune responses. Key among these are
GVHD, which has been difficult to separate from
GVL, and either upfront resistance of tumors to
GVL or late relapse. How to deliver GVL and pro-
mote immune reconstitution from donor T cells with
acceptable GVHD remains a central mantra in the
field. Overcoming these challenges would be facili-
tated by a detailed mechanistic understanding of
GVL resistance and GVHD. Identification of relevant
target structures, the type of effector cells necessary for
optimal and specific responses, and mechanisms of
action are among prerequisites for successful ‘‘next
steps.’’ We also need to understand the induction, ex-
pansion, and trafficking of immune responses, which
may allow specific recognition of hematopoietic tis-
sues from the host and not target organs of GVHD.
Knowledge of the factors that limit the effectiveness
of alloimmune responses to execute a specific antitu-
mor effect is essential to increase the likelihood of
success with no or limited toxicity. These factors in-
clude escape mechanisms of tumor cells to prevent
recognition and elimination by alloimmune responses,
which may include downregulation of the target struc-tures to be recognized, suppression of homing or inter-
action at the site of the tumor, or the development of
suppressive factors preventing the development of
the immune responses in vivo.
Future initiatives should be explored to identify
and overcome roadblocks preventing successful
application of allogeneic therapy for the treatment of
hematologic malignancies to exploit T cells, NK cells,
or antibody mediated mechanisms. Specific strategies
in mouse and in man may include (1) studies to better
understand mechanisms of trafficking, target recogni-
tion, and in vivo expansion of tumor specific responses;
(2) studies of mechanisms that suppress immune re-
sponses systemically or locally at the site of the tumor;
(3) studies on in vitro generation, expansion, and engi-
neering of specific immune cells for adoptive transfer;
(4) studies on the susceptibility of tumor stem cells to
immune attack; (5) induction of effective antitumor
immunity with vaccines or inhibition of negative regu-
latory pathways; and (6) high throughput screening for
antigens involved in antitumor responses using
genome wide analysis. Support for collaborative labo-
ratory studies and clinical trials as well as prospective
banking of human samples and collection of data will
facilitate translation of basic research into successful
clinical research strategies. Given the wealth of talent
with in the transplantation community, promoting
interactive program grants between institutions will
provide synergy, broaden the use of existing institution
core resources, and build on individual strengths to
move the field forward and systematically address
strategies needed to overcome post-transplant relapse.ACKNOWLEDGMENTS
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